UNICYCIVE THERAPEUTICS, INC. (UNCY) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -33.13M USD | Operating Income (Loss) |
| Revenue | (m) | |
| Cost of products and services | (m) | |
| Research and development | 9.58M USD | Research and Development Expense |
| Selling, general and administration | (m) | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-33.13M | (m) | (m) | $9.58M | (m) | (m) |
| 2026-03-31 | $-29.96M | (m) | (m) | $8.56M | (m) | (m) |
| 2025-12-31 | $-29.52M | (m) | (m) | $9.12M | (m) | (m) |
| 2025-09-30 | $-31.55M | (m) | (m) | $12.16M | (m) | (m) |
| 2025-06-30 | $-30.48M | (m) | (m) | $12.27M | (m) | (m) |
| 2025-03-31 | $-30.90M | (m) | (m) | $15.37M | (m) | (m) |
| 2024-12-31 | $-32.12M | (m) | (m) | $20.01M | (m) | (m) |
| 2024-09-30 | $-29.17M | (m) | (m) | $18.96M | (m) | (m) |
| 2024-06-30 | $-28.86M | (m) | (m) | $19.29M | (m) | (m) |
| 2024-03-31 | $-25.78M | (m) | (m) | $16.68M | (m) | (m) |
| 2023-12-31 | $-20.77M | $675.00K | (m) | $12.90M | (m) | -3077.63% |
| 2023-09-30 | $-19.79M | $675.00K | (m) | $12.51M | $439.00K | -2931.26% |
| 2023-06-30 | $-19.40M | $1.63M | (m) | $13.94M | $643.00K | -1193.30% |
| 2023-03-31 | (m) | (m) | (m) | $13.53M | $254.00K | (m) |
| 2022-12-31 | $-18.05M | $951.00K | (m) | $12.44M | $383.00K | -1898.21% |
| 2022-09-30 | $-15.48M | (m) | (m) | $9.96M | $680.00K | (m) |
| 2022-06-30 | $-14.64M | (m) | (m) | $8.93M | $589.00K | (m) |
| 2022-03-31 | $-11.78M | (m) | (m) | $7.56M | $418.00K | (m) |
| 2021-12-31 | $-8.98M | (m) | (m) | $6.08M | $245.00K | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-2.02M | (m) | (m) | $1.01M | $58.00K | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |